<DOC>
	<DOCNO>NCT02412670</DOCNO>
	<brief_summary>This phase II trial study well give chemotherapy surgery work treat patient aggressive upper urinary tract cancer . Drugs use chemotherapy , methotrexate , vinblastine , doxorubicin hydrochloride , cisplatin , gemcitabine hydrochloride , carboplatin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Removing affected upper urinary tract surgery recommend treatment upper urinary tract cancer , cause loss kidney function prevent patient able receive chemotherapy surgery . Giving chemotherapy surgery , kidney work maximum , may allow less tissue remove surgery may effective treat patient high grade upper urinary tract cancer .</brief_summary>
	<brief_title>Chemotherapy Before Surgery Treating Patients With High Grade Upper Urinary Tract Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate rate complete pathologic response ( pCR = pT0pN0 ) assess standard pathologic review attain neoadjuvant systemic chemotherapy nephroureterectomy . SECONDARY OBJECTIVES : I . To evaluate safety neoadjuvant systemic chemotherapy patient upper tract urothelial carcinoma precede nephroureterectomy . II . To evaluate recurrence-free survival patient treat neoadjuvant systemic chemotherapy precede nephroureterectomy . III . To evaluate event-free survival patient treat neoadjuvant systemic chemotherapy precede nephroureterectomy . IV . To evaluate bladder cancer-free survival patient treat neoadjuvant systemic chemotherapy precede nephroureterectomy . V. To evaluate cancer specific survival patient treat neoadjuvant systemic chemotherapy precede nephroureterectomy . VI . To evaluate renal functional outcome patient treat neoadjuvant systemic chemotherapy precede nephroureterectomy . TERTIARY OBJECTIVES : I . To collect pre-treatment post-treatment tumor tissue , peripheral blood mononuclear cell ( PBMC ) , peripheral blood plasma , urine specimens potential evaluation marker chemotherapy response/resistance . OUTLINE : Patients assign 1 2 treatment arm base baseline renal function . ARM A ( CREATININE CLEARANCE [ CRCL ] &gt; = 50 ) : Patients receive methotrexate intravenously ( IV ) 2-3 minute , vinblastine IV , doxorubicin hydrochloride IV , cisplatin IV 4 hour day 1 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . Patients without metastatic disease undergo nephroureterectomy lymph node dissection 21-60 day completion chemotherapy . ARM B ( 30 = &lt; CRCL &lt; 50 ) : Patients receive gemcitabine hydrochloride IV 30-60 minute day 1 8 carboplatin IV 30-60 minute day 1 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients without metastatic disease undergo nephroureterectomy lymph node dissection 21-60 day completion chemotherapy . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients must high grade upper tract urothelial carcinoma proven one following : Biopsy ; Urinary cytology 3dimensional upper urinary tract mass crosssectional imaging ; Urinary cytology mass visualize upper urinary tract endoscopy Patients must creatinine clearance &gt; = 30 ml/min determine CockcroftGault calculation 24hour urine creatinine clearance measurement within 28 day registration eligible study Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients must evidence metastatic disease clinically enlarge lymph node compute tomography ( CT ) magnetic resonance imaging ( MRI ) abdomen pelvis CT chest obtain within 28 day registration ( negative biopsy require lymph node &gt; 1 cm size confirm lack involvement ) ; patient lymph node &gt; 1 cm biopsy deem feasible eligible ; patient elevate alkaline phosphatase suspicious bone pain also undergo baseline bone scan evaluate bone metastasis Patients component small cell carcinoma eligible ; variant histology permit provide predominant ( &gt; = 50 % ) subtype urothelial carcinoma Patients must peripheral neuropathy &gt; grade 2 Patients must history allergy hypersensitivity methotrexate , vinblastine , doxorubicin ( doxorubicin hydrochloride ) , cisplatin , gemcitabine ( gemcitabine hydrochloride ) , carboplatin filgrastim pegfilgrastim Patients must leave ventricular ejection fraction ( LVEF ) &gt; = 50 % ( either multigated acquisition [ MUGA ] 2dimensional [ 2D ] echocardiogram ) within 28 day registration Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelets &gt; = 100,000/mm^3 Hemoglobin ( HgB ) &gt; = 9 Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 2 X institutional upper limit normal ( ULN ) Bilirubin within institutional normal limit ( &lt; 2.5 X ULN patient Gilbert 's disease ) Patients concomitant primary bladder/urethra allow , long site surgically resect noninvasive cancer ( &lt; cT1N0 ) Patients must another active second malignancy nonmelanoma skin cancer biochemical relapsed prostate cancer ; patient complete necessary therapy consider less 30 % risk relapse consider active second malignancy eligible enrollment For patient creatinine clearance meet &gt; = 50 ml/min must receive prior systemic doxorubicin Patients uncontrolled illness include , limited , ongoing active infection , symptomatic congestive heart failure , myocardial infarction last 3 month , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement eligible Patients know human immunodeficiency virus ( HIV ) combination antiretroviral therapy ineligible Patients must prior radiation therapy &gt; = 25 % bone marrow diseases prior systemic anthracycline therapy ; prior intravesical anthracycline therapy nonmuscle invasive urothelial carcinoma bladder permit Patients may history resectable urothelial cancer ( include neoadjuvant chemotherapy ) long patient meet one follow : pT0 , Tis , T1N0 evidence disease ( NED ) 2 year surgery chemotherapy ; pT23aN0 NED 3 year surgery chemotherapy ; &gt; pT3b , N+ NED 5 year surgery chemotherapy Women must pregnant breastfeeding ; female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy ; female childbearing potential woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Women childbearing potential sexually active male must use accepted effective method contraception abstain sexual intercourse duration participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>